Hiraki A - Search Results

1

Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.

Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M. Segawa Y, et al. Among authors: hiraki a, hiraki s. J Clin Oncol. 2010 Jul 10;28(20):3299-306. doi: 10.1200/JCO.2009.24.7577. Epub 2010 Jun 7. J Clin Oncol. 2010. PMID: 20530281 Clinical Trial.

2

Gingival metastasis in lung cancer.

Tanaka M, Hiraki A, Ueoka H, Bessho A, Kiura K, Takigawa N, Kodani T, Miyatake K, Hamada N, Kishimoto T, Tanimoto M, Harada M. Tanaka M, et al. Among authors: hiraki a. Oncol Rep. 2002 May-Jun;9(3):571-4. Oncol Rep. 2002. PMID: 11956629

3

Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.

Takigawa N, Fujiwara K, Ueoka H, Kiura K, Tabata M, Hiraki A, Shibayama T, Segawa Y, Kamei H, Hiraki S, Tanimoto M, Harada M. Takigawa N, et al. Among authors: hiraki a, hiraki s. Anticancer Res. 2003 Jan-Feb;23(1B):557-60. Anticancer Res. 2003. PMID: 12680145 Clinical Trial.

4

Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis.

Maeda T, Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Takigawa N, Hiraki A, Katayama H, Harada M. Maeda T, et al. Among authors: hiraki a. Jpn J Clin Oncol. 2000 Dec;30(12):534-41. doi: 10.1093/jjco/hyd139. Jpn J Clin Oncol. 2000. PMID: 11210162

5

Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy.

Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M, Harada M. Kawai H, et al. Among authors: hiraki a. Lung Cancer. 2002 Mar;35(3):305-14. doi: 10.1016/s0169-5002(01)00430-5. Lung Cancer. 2002. PMID: 11844606

6

Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2.

Hiraki A, Kiura K, Yamane H, Nogami N, Tabata M, Takigawa N, Ueoka H, Tanimoto M, Harada M. Hiraki A, et al. Lung Cancer. 2002 Mar;35(3):329-33. doi: 10.1016/s0169-5002(01)00424-x. Lung Cancer. 2002. PMID: 11844609

7

Primary signet-ring cell carcinoma of the lung with histochemical characterization.

Hiraki A, Ueoka H, Yoshino T, Tabata M, Kiura K, Tanimoto Y, Kamao T, Komoto R, Harada M. Hiraki A, et al. Anticancer Res. 2002 Mar-Apr;22(2B):1079-81. Anticancer Res. 2002. PMID: 12168904

8

Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia.

Hiraki A, Ueoka H, Bessho A, Segawa Y, Takigawa N, Kiura K, Eguchi K, Yoneda T, Tanimoto M, Harada M. Hiraki A, et al. Cancer. 2002 Oct 15;95(8):1706-13. doi: 10.1002/cncr.10828. Cancer. 2002. PMID: 12365018 Free article.

9

Hydronephrosis as a complication of adenocarcinoma of the lung.

Hiraki A, Ueoka H, Gemba K, Kuyama S, Kishino D, Tabata M, Kiura K, Tanimoto M, Harada M. Hiraki A, et al. Anticancer Res. 2003 May-Jun;23(3C):2915-6. Anticancer Res. 2003. PMID: 12926134

10

Hypercalcemia-leukocytosis syndrome associated with lung cancer.

Hiraki A, Ueoka H, Takata I, Gemba K, Bessho A, Segawa Y, Kiura K, Eguchi K, Yoneda T, Tanimoto M, Harada M. Hiraki A, et al. Lung Cancer. 2004 Mar;43(3):301-7. doi: 10.1016/j.lungcan.2003.09.006. Lung Cancer. 2004. PMID: 15165088

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

187 results

Search Page

Filters